Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Infusion preparation for dialysis patient

A technology for patients and pharmaceutical preparations, applied in blood diseases, drug delivery, extracellular fluid diseases, etc., to achieve the effect of reducing the dosage and improving the effect of dialysis treatment

Inactive Publication Date: 2009-07-01
EA PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] Although a variety of amino acid preparations are available for patients with renal failure, there are no literature or reports describing the use of these drugs to control serum phosphorus levels in appropriate ranges in dialysis patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Infusion preparation for dialysis patient
  • Infusion preparation for dialysis patient
  • Infusion preparation for dialysis patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0122] Example 1: Preparation of anti-anemia preparation (amino acid infusion)

[0123] The ingredients shown in Table 1 below were dissolved in water for injection in the amounts shown in the table. The solution was sterile filtered and placed in a glass bottle. The bottle was sealed and autoclaved to prepare an anti-anemia preparation (amino acid infusion).

[0124] The pH of the preparation is 6.6-7.6, and the osmotic pressure ratio is about 2.

[0125] Table 1:

[0126] ingredient 200mL L-Isoleucine 1.500g L-Leucine 2.000g L-lysine (as acetate) 1.400g L-methionine 1.000g L-phenylalanine 1.000g L-threonine 0.500g L-tryptophan 0.500g L-valine 1.500g

[0127] L-Alanine 0.600g L-Arginine 0.600g L-Aspartic Acid 0.050g L-glutamic acid 0.050g L-histidine 0.500g L-Proline 0.400g L-serine 0.200g L-tyrosine 0.100g Glycine 0.300g Total amino acids 12.200g A...

Embodiment 2

[0129] Example 2. Determination of the ability of pharmaceutical preparations to improve anemia and reduce the dosage of erythropoietin

[0130] 18 cases of chronic renal failure patients receiving hemodialysis (HD: 9 cases) or hemodiafiltration (HFD: 9 cases) were administered the exemplary anti-anemia preparation of the present invention to check that the preparation improves anemia and reduces the administration of erythropoietin Capacity.

[0131] [method]

[0132] The commercially available amino acid infusion solution "NEOAMYU (registered trademark)" (200 mL formulation, Ajinomoto Pharma Co., Ltd.) prepared according to Example 1 was used.

[0133]In the week before the administration period, necessary diagnosis, inspection and testing were performed on the first dialysis day (week 1 or week 2). From 1 week after diagnosis to 12 weeks and 1 day (the 37th dialysis), the "NEOAMYU" formulation was continuously administered. Specifically, 1 bottle (200 mL) of the preparation was...

Embodiment 3

[0140] Example 3: Determination of the ability of the above pharmaceutical preparations to control serum phosphorus levels

[0141] The exemplary serum phosphorus control preparation of the present invention was administered to 8 patients with chronic renal failure undergoing hemodialysis (HD) to check changes in serum phosphorus levels.

[0142] [method]

[0143] A commercially available amino acid infusion solution "NEOAMYU" (200 mL formulation, Ajinomoto Pharma Co., Ltd.) prepared according to Example 1 was used.

[0144] In the week before the administration period, necessary diagnosis, inspection and testing were performed on the first dialysis day (week 1 or week 2). From 1 week after diagnosis to 12 weeks and 1 day (the 37th dialysis), the "NEOAMYU" formulation was continuously administered. Specifically, 1 bottle (200 mL) of the preparation was injected into the venous side of the dialysis circuit during each dialysis. The preparation was input throughout the course of dia...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An infusion preparation which is to be used in dialyzing a dialysis patient for ameliorating the anemic state by improving nutritional conditions, thus reducing the dosing amount of erythropoietin, controlling the serum phosphorus level to thereby regulate the serum phosphorus level within a definite range and inhibiting the protein catabolism and which contains at least essential amino acids, characterized in that the amino acids are composed of at least L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and L-cysteine and the ratio of essential amino acids : non-essential amino acids is 2.5 or higher.

Description

Technical field [0001] The present invention relates to infusions for dialysis patients, and particularly to the treatment of anemia in dialysis patients receiving hemodialysis, hemodiafiltration or other hemodialysis treatments. The present invention also relates to a method for improving anemia in patients with chronic renal failure, which requires reducing the amount of erythropoietin (EPO), which is a hematopoietic hormone administered to patients with chronic renal failure to treat anemia. Background technique [0002] Hemodialysis (HD) is a blood purification technique used to treat patients with chronic renal failure. One of the difficulties of hemodialysis is that it not only removes excreta from the patient's body, it also removes useful components, such as amino acids. Recently, long-term treatment of dialysis technology often complicates disease symptoms known as dialysis-related amyloidosis, which is developed from the accumulation of the mid-molecular protein β-2 mic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61K9/08A61K31/401A61K31/405A61K31/4172A61P3/12A61P7/06
CPCA61K9/0019A61K31/4172A61K31/405A61K31/401A61K31/198A61P3/02A61P3/12A61P7/06
Inventor 杉山隆之
Owner EA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com